Comparing eptinezumab with onabotulinumtoxinA in the treatment of chronic migraine: a real-world evidence study.

J Headache Pain · 2025 · PMC12261790 · PMID 40660133

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

By contrast, reductions of VAS and MIDAS scores did not reach statistical significance for either treatment.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.